{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:23:22Z","timestamp":1791033802159,"version":"4.1.0"},"reference-count":40,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"St. John\u2019s University Research Seed Grant","award":["579-1110-7002"],"award-info":[{"award-number":["579-1110-7002"]}]},{"name":"National Institute of Health-USA","award":["1R15GM116043-01"],"award-info":[{"award-number":["1R15GM116043-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>ABCB1 is one of the major drug efflux transporters that is known to cause multidrug resistance (MDR) in cancer patients receiving chemotherapy for the treatment of solid tumors and hematological malignancies. Inhibition of ABCB1 efflux function is important for maintaining the intracellular concentration of chemotherapeutic drugs. Here, we evaluated ciprofloxacin for its ability to reverse MDR caused by the overexpression of ABCB1. Cytotoxicity of ciprofloxacin was determined by the MTT assay. The chemosensitizing effects of ciprofloxacin were determined in combination with ABCB1 substrates. The intracellular accumulation and efflux of ABCB1 substrates was measured by a scintillation counter, and protein expression was determined by the Western blotting. Vanadate-sensitive ATPase assay was performed to determine the effect of ciprofloxacin on the ATPase activity of ABCB1, and docking analysis was done to determine the interaction of ciprofloxacin with ABCB1. Ciprofloxacin significantly potentiated the cytotoxic effects of ABCB1 substrates in ABCB1-overexpressing cells. Furthermore, ciprofloxacin increased the intracellular accumulation and decreased the efflux of [3H]-paclitaxel without altering the expression of ABCB1. Ciprofloxacin stimulated the ATPase activity of ABCB1 in a concentration-dependent manner. Our findings showed that ciprofloxacin potently inhibits the ABCB1 efflux function and it has potential to be developed as a combination anticancer therapy.<\/jats:p>","DOI":"10.3390\/ijms20020268","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T04:10:16Z","timestamp":1547179816000},"page":"268","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates"],"prefix":"10.3390","volume":"20","author":[{"given":"Pranav","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ling","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"},{"name":"Department of Histology and Embryology, Weifang Medical University, Weifang 261053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunali V.","family":"Ashar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant M.","family":"Karadkhelkar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8033-3291","authenticated-orcid":false,"given":"Sabesan","family":"Yoganathan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Fan, Y.F., Zhang, W., Zeng, L., Lei, Z.N., Cai, C.Y., Gupta, P., Yang, D.H., Cui, Q., Qin, Z.D., and Chen, Z.S. (2018). Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Lett.","DOI":"10.1016\/j.canlet.2018.01.021"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1208\/s12248-015-9757-1","article-title":"Multidrug Resistance Proteins (MRPs) and Cancer Therapy","volume":"17","author":"Zhang","year":"2015","journal-title":"AAPS J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","article-title":"Modulating ROS to overcome multidrug resistance in cancer","volume":"41","author":"Cui","year":"2018","journal-title":"Drug Resist. Updat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13848","DOI":"10.3390\/molecules190913848","article-title":"Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance","volume":"19","author":"Anreddy","year":"2014","journal-title":"Molecules"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/17425255.2016.1145655","article-title":"Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer","volume":"12","author":"Gupta","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2017.03.011","article-title":"Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study","volume":"396","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhang, X.Y., Zhang, Y.K., Wang, Y.J., Gupta, P., Zeng, L., Xu, M., Wang, X.Q., Yang, D.H., and Chen, Z.S. (2016). Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. Molecules, 21.","DOI":"10.3390\/molecules21091236"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2018.02.040","article-title":"Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo","volume":"424","author":"Zhang","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1016\/j.bmcl.2017.09.009","article-title":"Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors","volume":"27","author":"Gujarati","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1159\/000487578","article-title":"Voruciclib, a Potent CDK4\/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells","volume":"45","author":"Gupta","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"39276","DOI":"10.18632\/oncotarget.5747","article-title":"A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo","volume":"6","author":"Anreddy","year":"2015","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1002\/jcb.25975","article-title":"GSK1904529A, a Potent IGF-IR Inhibitor, Reverses MRP1-Mediated Multidrug Resistance","volume":"118","author":"Gupta","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drup.2012.01.005","article-title":"Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance","volume":"15","author":"Shukla","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","article-title":"Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents","volume":"142","author":"Beretta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.canlet.2016.09.025","article-title":"PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia","volume":"383","author":"Gupta","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"29760","DOI":"10.18632\/oncotarget.15964","article-title":"Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells","volume":"8","author":"Wen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bjp.0706974","article-title":"Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters","volume":"150","author":"Schrickx","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1039\/C5OB00246J","article-title":"Discovery of 4-acetyl-3-(4-fluorophenyl)-1-(p-tolyl)-5-methylpyrrole as a dual inhibitor of human P-glycoprotein and Staphylococcus aureus Nor A efflux pump","volume":"13","author":"Bharate","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3892\/or.2017.5410","article-title":"Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin","volume":"37","author":"Yuan","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ejmech.2018.04.012","article-title":"Synthesis and biological evaluation of 2,5-disubstituted furan derivatives as P-glycoprotein inhibitors for Doxorubicin resistance in MCF-7\/ADR cell","volume":"151","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.biopha.2018.02.055","article-title":"Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it","volume":"100","author":"Li","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s11033-018-4220-x","article-title":"Ciprofloxacin: From infection therapy to molecular imaging","volume":"45","author":"Naqvi","year":"2018","journal-title":"Mol. Biol. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejmech.2018.01.078","article-title":"Ciprofloxacin derivatives and their antibacterial activities","volume":"146","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1753-5174.2010.00032.x","article-title":"Is Ciprofloxacin a Substrate of P-glycoprotein?","volume":"4","author":"Park","year":"2011","journal-title":"Arch. Drug Inf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1128\/AAC.48.7.2673-2682.2004","article-title":"Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter","volume":"48","author":"Michot","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Beberok, A., Wrze\u015bniok, D., Rok, J., Rzepka, Z., Respondek, M., and Buszman, E. (2018). Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53\/Bax\/Bcl-2 signaling pathway. Int. J. Oncol.","DOI":"10.3892\/ijo.2018.4310"},{"key":"ref_29","first-page":"956","article-title":"The effect of ciprofloxacin on the growth of B16F10 melanoma cells","volume":"13","author":"Jaber","year":"2017","journal-title":"J. Cancer Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.5506\/APhysPolB.42.859","article-title":"The influence of ciprofloxacin on viability of A549, HepG2, A375.S2, B16 and C6 cell lines in vitro","volume":"68","author":"Kloskowski","year":"2011","journal-title":"Acta Pol. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yadav, V., Varshney, P., Sultana, S., Yadav, J., and Saini, N. (2015). Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1560-y"},{"key":"ref_32","first-page":"91","article-title":"Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo","volume":"442","author":"Gupta","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcp.2018.10.028","article-title":"Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance","volume":"158","author":"Ji","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3389\/fphar.2018.01236","article-title":"VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters","volume":"9","author":"Ji","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0076-6879(98)92039-0","article-title":"Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells","volume":"292","author":"Ambudkar","year":"1998","journal-title":"Methods Enzymol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1124\/mol.65.6.1485","article-title":"High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter","volume":"65","author":"Hegedus","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.3892\/or.2013.2362","article-title":"Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10)","volume":"29","author":"Deng","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1107\/S1399004715000978","article-title":"Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein","volume":"71","author":"Szewczyk","year":"2015","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1021\/acs.jmedchem.7b01340","article-title":"Comprehensive Synthesis of Amino Acid-Derived Thiazole Peptidomimetic Analogues to Understand the Enigmatic Drug\/Substrate-Binding Site of P-Glycoprotein","volume":"61","author":"Patel","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/2\/268\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:25:10Z","timestamp":1760185510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/2\/268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1]]}},"alternative-id":["ijms20020268"],"URL":"https:\/\/doi.org\/10.3390\/ijms20020268","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,11]]}}}